Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cytotekk and all Anyone live in the state of New York and have shares of "AVTX" ?? [Please post to other boards..]
Even one share..
Thank you Jolyn
ironyman "Anyone willing to give me their proxy to"
Yes when the time comes..Don't show all your cards..
Let "AVTX" guess a little..
All of us are on war footing to save our investment..
and need start marching in one unit.
All of us can add to the force of the unit..
Ball has to show something Monday or I will
file with the SEC Tueday..Unless you or Cytotekk or
gold-nugget..Wants me to hold off with good reason..
To get to me fast post to in IHub or Yahoo "AVTX" board.
Its hard for me to post in RB..
We can not set on this 30 days Speed counts.
IMO Thank You Jolyn
Cytotekk "asking us to wait a bit until things are explained by Mr. Ball."
24hr sounds fair..I won't set on this long..
Now good old Hockypond is the one that showed me "DMXP" and I am setting on that worthless paper..
Thank you for posting here..in IHub
Please pass this to the other boards
http://www.qwoter.com/profiles/item.php?id=100&dir=1
Overview Advance Technologies Inc. is a global supplier of Infrared safety equipment and a market leader in providing solutions for safety and vision applications.
Symbol AVTX
Outstanding Shares 39,527,897 as of 2006-12-31
Officers Gary E. Ball, President
Address 716 Yarmouth Road Suite 215
Palos Verdes Estates, CA 90274
United States
Phone Number 310-265-7776
Fax Number N/A
Website URL http://www.avtx.com
Email Address BaG370@aol.com
Insider
Relationship Shares
Traded Average
Price Total
Amount Shares
Owned Filing
2005-10-18
Sale(C) 2005-11-02
12:16 pm ADVANCE TECHNOLOGIES INC AVTX Ball Gary Edward
(President
10% owner) 1,000,000 $0.033 $33,000
http://www.secform4.com/insider-trading/1343155.htm
http://sec.edgar-online.com/2000/01/21/07/0001095273-00-000004/Section3.asp
IMO Thank you Jolyn
All of us should E-Mail Fox news now...
I can't do it I am in the lower 48 and need to keep a low profile..For the most part I am useing only Hotspots for internet..
This type of News is Fox's cup of tea..
I will try to file with the SEC tonite...
If there is going to be a fight to save our investment I can start a Yahoo E-Group ....
Could some one re-post this post to RB..
IMO Thank you Jolyn
gold-nugget please explane this news.. It seems you knew something before the rest of us..
IMO Thank you Jolyn
Prodan This is not "EFTI" Board !! Your last two post
is "EFTI" spam..
Pump your junk stock on another board..
No need to replay..
IMO Thank you Jolyn
NANOBAC PHARMACEUTICALS INC
Form:10KSB/A Filing Date:3/30/2004 Jump to : -- Use Sections To Navigate Through The Document -- 10KSB/A FORM 10KSB/A Item 1. The Business Item 2. Properties Item 3. Legal Proceedings Item 4. Submission of Matters to a Vote of Security Holders Item 5. Market for Registrant's Common Stock and Related Shareholder ... ITEM 6. Selected Financial Data Item 7. Management's Discussion and Analysis of Financial Condition ... Liquidity and Capital Resources Item 7a: Quantitative and Qualitative Risk ITEM 8. Financial Statements and Supplementary Data ITEM 9. Changes in and Disagreements with Independent Auditors ... ITEM 10. Directors and Executive Officers of the registrant ITEM 11. Executive Compensation ITEM 12. Security Ownership of Certain Beneficial Owners and ... ITEM 13. Certain Relationships and Related Transactions ITEM 14. Controls and Procedures ITEM 15. Exhibits, Financial Statement Schedules and Reports ... BALANCE SHEET EXHIBIT INDEX SIGNATURES Independent Auditors' Report INDEPENDENT AUDITORS' REPORT BALANCE SHEET NOTES TO CONSOLIDATED FINANCIAL STATEMENTS EXHIBIT 3.1 Articles of Amendment to the Articles of Incorporation of EXHIBIT 10.4 EXHIBIT 10.10 EXHIBIT 10.11 EXHIBIT 21.1 SUBSIDIARIES EXHIBIT 23.1 CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS EXHIBIT 23.2 EXHIBIT 31.A EXHIBIT 31.B Format : HTML RTF Sections Excel Original PDF File Back
Item 1. The Business
Overview
Nanobac is a biolifescience company. Our business is the study and development
of therapeutic and diagnostic technologies related to the novel pleomorphic
pathogen known as nanobacterium sanguineum ("Nanobacteria"). Our primary purpose
is to use our discoveries, science and innovation to dramatically improve
people's lives. Our corporate goals are to launch a stream of products that will
impact the delivery of healthcare.
Business Applications
[Graphic Omitted]
Building a Leading Company in Nanobacteria Applications
Healthcare
Prevention, detection, treatment, and management of illness at the point of
patient care through the services offered by the medical and allied health
professions.
Biomedical
Application of biological and physiological principles to healthcare.
Bioindustrial
Application of biological and physiological principles to the biomedical
industry.
Healthcare Strategy
We are currently pursuing concurrent paths to provide earlier, easier and more
accurate diagnosis and treatment of degenerative and other pathologic
calcification diseases. Taking advantage of our diagnostic assays, combined with
our potential therapies, we will offer a change to the way pathological
calcifications are managed. The cost savings from our products occur at every
stage of the disease progression:
[GRAPHIC OMITTED]
o Earlier screening allows:
(a) Earlier diagnosis
(b) fewer physician office visits, less expensive, more accurate care
(c) medical management rather than surgical intervention
o Definitive nanobacterial diagnosis allows:
(a) earlier referral of diseased patients
(b) earlier initiation of the proper therapy
o Determination of nanobiotic therapy allows:
(a) more targeted and cost-effective therapy
(b) better clinical outcomes
o Monitoring nanobacterial progression/regression allows:
(a) optimization of therapeutic regimen for best clinical outcome
(b) prophylactic treatment and disease prevention
4
Initially, use of our diagnostic and therapeutic products will be adjunctive
with current procedures. Over time, as the value of the proprietary serological
tests are established and the product line expands to include further
serological and genetic diagnostic technology, our diagnostic work-ups may
reduce costly and time consuming protocols.
Market Positioning
Our products and services will be marketed as follows:
o Unique. We believe that our test for diagnosing nanobacteria is simpler and
more cost effective than our competitors.
o Expert Source. Remaining closely involved on a continuing basis with physician
and scientific thought leaders will be a cornerstone of our philosophy and
continued product development. We will support and present a broad number of
clinical studies which create publications and the adoption of products by the
physician results. The clinical results and patient reports will contain
in-depth analyses and discussion of the diagnoses as well as prescribed therapy
recommended by our medical advisory staff.
o Patented Technology. The initial test for diagnosing nanobacteria was
developed by two scientists in the area of bacteriology research. While the
underlying tests used to diagnose nanobacteria are relatively straight forward,
their application for disease states relies on the specificity of proprietary
reagents isolated and developed by Neva Ciftcioglu, PhD and Olavi Kajander, MD,
PhD. We own these patents as a result of our acquisition of Nanobac OY.
5
Products
[GRAPHIC OMITTED]
Diagnostic Development Strategy
Diagnostic - The Company's diagnostic products will be developed in three
phases:
Phase I: Nanobac has a commercially available serology test for the
identification of nanobacterial antibodies and antigens. Oxoid is the
distributor in the UK, Europe, Brazil and Australia. With combined research and
commercial results, Nanobac has established a database of serum specimens and
clinical data related to the diagnosis of nanobacteria. These technologies were
developed by Neva Ciftcioglu, PhD and Olavi Kajander, MD, PhD. at the University
of Kuopio in Finland, and Nanobac OY of Finland. Under Dr. Kajander's
supervision and using protocols he established, the Company utilizes its
database to provide a detailed diagnostic analysis. The analysis includes
reference to research studies, observations from similar and contrasting sets of
samples. The initial tests are the only simple blood serum tests commercially
available for clinicians and researchers for screening for Nanobacterium
sanguineum. Nanobac is consulting with a Contract Research Organization in order
to reach 510k status. 510k status is the premarket notification provisions of
the 1976 Medical Device Amendments to the Food, Drug, and Cosmetic (FD&C) Act as
amended by the Safe medical Devices Act of 1990 and is intended to serve as a
screening mechanism to allow for marketing of medical devices with a reasonable
assurance of safety and effectiveness.
Phase II: We will broaden the general cardiovascular serological products with
our proprietary serology product. Our diagnostic will become a key metric in the
work up of cardiovascular patients. The current serodiagnostic cardiovascular
market is expansive. and does not have a stand alone predictive or diagnostic
marker. Nanobac will pursue a pre-market approval (PMA) from the FDA specific to
the cardiac marker claim.
6
Phase III: Promotion in other disease sites. With a preeminent position in
defining nanobacteria clinical pathways of care, we will support and present a
broad number of clinical studies on other disease sites. This will lead to the
adoption of products by the appropriate physician specialist. We intend to
pursue the urology market with a strategy similar to cardiology.
We are fortunate to have an ISO 9000 facility, in Finland, that produces our
antibodies and antigens for the nanobacteria diagnostic serology test. The
components that are required to complete the Elisa test kit are commercially
available throughout the world. We are not dependent on any customer or vendor
at this time.
Therapeutic
[GRAPHIC OMITTED]
Therapeutic Development Strategy
We intend to capitalize on our patent for the eradication of nanobacteria. The
therapies that evolve from the patent to treat Nanobacterium Sanguineum
infection, may contribute to the treatment of cardiovascular, urologic, and
other degenerative diseases. The Nanobiotic therapy previously identified as
NanobacTx, Urobac, and Dermabac have been discontinued. NanobacTX was launched
by the predecessor company approximately three years ago. The previous
management team at Nanobaclabs reasoned that they were following the tenets of
Section 503a of the Federal Food, Drug and Cosmetic Act concerning "pharmacy
compounding", and that utilization of previously approved drugs was exempt from
the IND process. The new management, after legal, government, regulatory, and
industry consultations, voluntarily withdrew the aforementioned Nanobiotic
therapies from the market. New management regarded the previous management's
view as not supported by the FDA's current interpretation of section 503a.
NanobacTX had grown to 14,000 prescriptions since inception.
7
Licensing of late stage development compounds is also a strategy that we will
employ for compounds that require minimal development for filing to obtain FDA
approval. The lower cost and lower risk of this strategy coupled with the short
time to market for these compounds, is aligned with the overall Nanobac business
plan. We are also seeking better delivery methods that will improve patient
compliance.
Our ongoing therapeutic development strategy will include our proprietary
compounds as well as identification of compounds and projects that are in Phase
III (see government regulation for description of Phase III). Compounds and
projects can include mechanisms of action and mechanisms of drug delivery. We
provide unique opportunities for these companies to realize the significant
potential of their various antibiotic projects.
Healthcare Market
Market Size
Pathologic calcifications are treated in a number of ways, depending on the
seriousness of the disease. For example, Coronary Heart Disease (CHD),
Polycystic Kidney Disease (PKD), and Kidney Stone patients are managed with
lifestyle changes and medications. Others with severe CHD or PKD may need
surgery. In any case, once CHD or PKD develop, they require lifelong management.
Listed below are the costs associated with these disease states.
Health Dollars Spent
Disease Site (in millions of US$) Source
Coronary Heart Disease (CHD) 325,000,000,000 AHA
Kidney Stones 1,830,000,000 NIDDK
Polycystic Kidney Disease (PKD) 1,000,000,000 NIDDK
Prostatitus 1,330,000,000 NAMCS
329,160,000,000
--------------------------------------------------------------------------------
Additional biomedical research and clinical studies are planned or underway to
document nanobacteria's role in the development of Atherosclerosis, Gall Stones,
Chronic Prostatitis, Diabetes, Arthritic Spurs, Cataracts, Scleroderma, Kidney
Cysts and Kidney Stones, certain Breast Pathology, Polycystic Kidney Disease
(PKD), Solid Tumor Pathologies, Immunosuppressed Conditions, Dental Pulp Stone,
and Neurodegenerative Disease.
8
Cardiac
The most serious and widespread of the diseases caused by calcified plaque are
atherosclerosis (hardening of the arteries) and coronary heart disease (CHD).
Coronary artery disease (CAD) is CHD of the heart's arteries. Atherosclerosis in
the carotid arteries, the primary blood supply to the brain, affects more than
one-third of individuals 51 to 55 years old and over half of individuals 61-65
years of age. CAD begins as coronary artery calcification that leads to
atherosclerosis before developing into CAD. This process is generally slow and
can begin in childhood. Coronary artery disease remains the #1 killer of adult
males in the U.S. Cardiovascular diseases represent 26.7% of all physician
visits and 26.1% of all scripts in the United States. CAD is the most common
form of heart disease affecting approximately 1.3 million Americans. Over 50% of
the people who die suddenly of CAD had no symptoms. These major public health
issues, in the U.S. and worldwide, were chosen as the focus of our initial
research and development efforts.
Chest pain (angina) or shortness of breath may be the earliest signs of CAD. A
person may feel heaviness, tightness, pain, burning, pressure, or squeezing,
usually behind the breastbone but sometimes also in the arms, neck, or jaws.
These signs usually bring the patient to a doctor for the first time. In fact,
50% of the people having heart attacks, the heart attack was the first symptom
of heart disease. It is important to know that there is a wide range of severity
for CAD. Some people have no symptoms at all, some have mild intermittent chest
pain, and some have more pronounced and steady pain. Still others have CAD that
is severe enough to make normal everyday activities, like walking to the
mailbox, difficult. Because CAD varies so much from one person to another, the
way a doctor diagnoses and treats CAD will also vary a lot.
CAD is normally diagnosed using one or a combination of several diagnostic tests
Electron Beam Computed Tomographic Imaging (EBCT), Echocardiography,
Ventriculogram, Electrocardiogram (ECG or EKG), Coronary angiography, exercise
thallium test, or Positron emission tomography (PET) scanning. CAD can be
controlled or treated with various techniques: i) medication (beta blockers,
calcium channel blockers, or nitroglycerine), ii) transcatherter interventions
(Percutaneous transmyocardial revascularization (PTMR), Atherectomy,
Angioplasty, Stent, or Laser ablation), or iii) surgery (coronary artery bypass
or Transmyocardial laser revascularization (TMLR)). With nanobacteria being
present in atherosclerosis one may ask themselves if the current diagnostic
tools and therapeutic treatments available for CAD are insufficient to address
the problem. The nanobacterial blood test, NB2, may prove to be a new metric in
the diagnosis and treatment of CAD.
CAD is treated in a number of ways, depending on the seriousness of the disease.
For many people, CAD is managed with lifestyle changes and medications. Others
with severe CAD may need surgery. In any case, once CAD develops, it requires
lifelong management.
9
Urological
Kidney stones are one of the most common disorders of the urinary tract;
patients made more than 1.3 million visits to health care providers to have
their stones treated in 1997. In 1999, more than a quarter million hospitalized
patients had a diagnosis of kidney stones. An estimated 10 percent of people in
the United States will have a kidney stone at some point in their lives. Men
tend to be affected more frequently than women.
A kidney stone is a solid piece of material that forms in the kidney out of
substances in the urine. A stone may stay in the kidney or break loose and
travel down the urinary tract. A small stone may pass all the way out of the
body without causing too much pain. A larger stone may get stuck in a ureter,
the bladder, or the urethra. A problem stone can block the flow of urine and
cause great pain. Stone that will not pass by itself may require: extracorporeal
shockwave lithotripsy, tunnel surgery (percutaneous nephrolithotomy), or
ureteroscope extraction. Kidney stones are diagnosed by x ray, sonogram, or IVP
(intravenous pyelogram).
Greater than 90% of human kidney stones are positive for nanobacteria. It is
interesting to note that astronauts have preponderance for kidney stone
formation. Lack of gravity causes bone loss causing increased calcium in the
blood therefore nanobacteria is an important catalyst for stone formation. Not
only in astronauts is nanobacteria important in stone formation but it has also
been shown to cause stone formation in rats. With further studies Nanobac
Pharmaceuticals intends to change the course of diagnosing and treating the many
patients with these painful kidney stones. Polycystic kidney disease (PKD) is a
genetic disorder characterized by the growth of numerous cysts in the kidneys.
The cysts are filled with fluid. PKD cysts can slowly replace much of the mass
of the kidneys, reducing kidney function and leading to kidney failure. PKD can
cause cysts in the liver and problems in other organs, such as the heart and
blood vessels in the brain. These complications help doctors distinguish PKD
from the usually harmless "simple" cysts that often form in the kidneys in later
years of life.
In the United States, about 500,000 people have PKD, and it is the fourth
leading cause of kidney failure. Medical professionals describe two major
inherited forms of PKD and a noninherited form. The signs of PKD include: pain
in the back and lower sides, headaches, urinary tract infections, blood in the
urine and cysts in the kidneys and other organs. Diagnosis of PKD is obtained
by: ultrasound imaging of kidney cysts, ultrasound imaging of cysts in other
organs, family medical history (genetic testing). PKD has no cure. Treatments
include: medicine and surgery to reduce pain, antibiotics to resolve infections,
dialysis and transplantation to replace functions of failed kidneys.
10
Studies have shown that in PKD patients 100% of kidney cyst fluids and urine
were positive for nanobacteria. Nanobacteria may cause damage to kidney cells
allowing cysts to form in these PKD patients that have defective tissue
regeneration. Again with nanobacteria being present in PKD patients one may ask
themselves if the current diagnostic tools and therapeutic treatments available
for PKD are insufficient to address the problem. Nanobac Pharmaceuticals plans
to initiate research trials that will evaluate the link between nanobacteria and
PKD. We are positioned to provide novel diagnostics and research potential
nanobacterial treatments for this disease with limited and costly treatment
options.
Prostatitis is a painful inflammation of the prostate gland. Prostatitis' cause
is not known, but can be classified as acute or chronic bacteria prostatitis.
Symptoms may include pain while urinating or ejaculating, chills or fever,
perineal, testicular, bladder or low back pain. Some common methods for
diagnosis are a digital rectal exam (DRE), transrectal ultrasound or a Prostate
Specific Antigen (PSA) test. Other methods are urine samples to determine
inflammation or infection, cystoscopy or urine flow studies to measure the
strength of the flow. Treatment usually includes prolonged antibiotic
treatments, alpha-blockers, anti-inflammatory drugs, vitamins, repetitive
prostatic massage or heat therapies. If antibiotic treatment is unsuccessful,
surgery (transurethral resection or TURP) may be done. This delicate surgery can
cause sterility, impotence, and/or incontinence. Prostatitis is difficult to
diagnose and is therefore difficult to treat. Some patients may never experience
relief and may have to cope with the condition for the remainder of their lives.
According to urologist Thomas Stamey, up to 50% of all men experience symptoms
of prostatitis during their lifetimes.
Competition
Competition in the biotechnology and pharmaceutical industries is intense and
comes from many and varied sources. We do not believe that any of the industry
leaders can be considered dominant in view of the rapid technological change in
the industry. Many of these companies have substantially greater financial,
marketing, research and development and human resources than us. Most large
pharmaceutical companies have considerable experience in undertaking clinical
trials and in obtaining regulatory approval to market pharmaceutical products.
The market for providing physicians and managed care organizations with
nanobacteria related disease management and services are just emerging, and we
are among the leaders in providing a comprehensive approach to managing
nanobacterial diseases.
The general market for providing primary care physicians, cardiologists, and
urologists with specialized serological diagnostic services for detection,
diagnosis, prognosis and monitoring is highly competitive and dominated by Quest
and Labcorp. Their competitive strength lies in their service capabilities, i.e.
to provide local couriers for specimen pickup and broad-based contracting
ability with managed care organizations.
11
The general market for providing primary care physicians, cardiologists, and
urologists with therapies for cardiovascular disease is also highly competitive
and includes both pharmaceutical and medical device companies. The treatment of
nanobacteria infection is a paradigm shift for these physicians as was h.Pylori
for the practicing gastroenterologist.
We believe that we will be able to grow and defend our specialized nanobacteria
related disease market niche due to our expertise in the field, our disease
management approach, and our technology leadership.
Patents and Intellectual Property
We have filed three patents, and received allowance on all three filings. We
intend to try to take steps to aggressively protect and expand our intellectual
property, which is a core strength. Our patents are summarized below.
Patent Antibody Extraction Protocol - Growth factor preparation of thymocyte
cell culture medium its production and use [US 5,776,778; WO9534317]
The present invention relates to a growth factor preparation derived from a
mixed lymphocyte culture, and a process for its production. The invention also
relates to a cell culture medium containing said growth factor preparation. The
invention further relates to a process for culturing plasma cells and producing
antibodies by using said cell culture medium.
12
Patent Diagnostic - Culture and detection method for sterile-filterable
autonomously replicating biological particles. [US 5,135,851,2008; EU 0460414,
(valid in 13 EU countries),2010]
Novel autonomously replicating biological particles resembling bacteria and
having most surprising properties were discovered from cell culture sera and
other biological samples alleged to be sterile according to the current testing
methods. These slowly growing agents named nanobacteria are smaller than any
known cell-walled bacteria. They pass through sterile filters, even with pore
sizes smaller than their diameter. They cannot be cultured on any standard
microbiological media. With the isolation and detection methods provided here
they are commonly detectable in animal or human serum. This patent holds for
methods of their culture, detection, purification, and elimination and described
the necessary reagents for that. Autonomously replicating particles can be
cultured in RPMI 1640, or in DMEM, or in other cell culture media. Optimal
growth can be obtained by supplementing the culture medium with 10-20% sterile
fetal bovine serum. Addition of small amounts of D,L or L selenomethionine
together with nucleotide precursors may improve growth. Culture is started by
addition of the test sample to the medium in a cell culture vial which is
thereafter incubated under standard mammalian cell culture conditions for at
least 15 days. Biological samples are preferably sterile-filtered before culture
through 0.22 micron filters. The growth of nanobacteria, if present, can be seen
using microscopy at high magnification. The organisms can be made more visible
by DNA staining and immunostaining done either separately or simultaneously to a
fixed preparation. Nanobacteria can be cultured without mammalian cells, but
co-culture together with an adherent cell line like 3T6 is useful because 3T6
cells can take nanobacteria inside the cells. This aids the staining of the
preparations. Intracellular agents are not lost during fixation and staining.
Nanobacterial antigens can be prepared by specific culture, harvest,
purification and solubilization methods. Immunization of rabbits with the
solubilized antigen (treatment with proteinase K and with 1 N HCI) produces
highly specific antibodies to nanobacteria. Gamma-irradiation of culture serum
at 2.5-4.0 megarads, preferably in addition with treatment using solid-phase
bound antibodies enables preparation of nanobacteria-free serum. Use of this
serum creates sterile culture medium for the culture and detection of
nanobacteria. Double staining combining Hoechst No. 33258 stain and
immunofluorescence specifically distinguishes nanobacteria from other cell
culture contaminants.
Patent Therapeutic - [US Patent 6,706,290; EP 1094711] Methods for eradication
of Nanobacteria
Nanobacteria contribute to pathological calcification in the human and animal
body, including diseases such as kidney stones, salivary gland stones, dental
pulp stones and atherosclerosis. The present invention provides methods for
sterilizing articles contaminated with nanobacteria. The present invention also
provides methods of treating patients infected with nanobacteria. In particular,
the present invention provides a method for preventing the recurrence of kidney
stones in a patient that has suffered from kidney stones, comprising
administration of an antibiotic, a bisphosphonate, or a calcium chelator, either
alone or in combination, in an amount effective to inhibit or prevent the growth
and development of nanobacteria.
13
Our Science
The term "nanobacteria" is short for its scientific name Nanobacterium
sanguineum, a Latin term for blood nanobacteria. Though the human body does not
recognize nanobacteria as harmful, it has been shown to be implicated in the
formation of disease-causing calcified plaque in the circulatory system and
vital organs. We conduct research of degenerative diseases stemming from
nanobacterial infections. We are developing unique technologies for early
accurate diagnoses of nanobacterial infection, and eradication methods which
allow physicians to effectively manage the clinical symptoms of the disease,
improve therapeutic results, and as an outcome, lower overall medical costs.
We have patents with respect to the identification and eradication of the
pathogen Nanobacterium Sanguineum. Although we possess intellectual property
with Bioindustrial, Biomedical and Healthcare implications, we will focus
initially on Healthcare.
We plan to leverage our intellectual property and proprietary technology to
establish value and credibility with clinicians and researchers specializing in
cardiovascular and other diseases. From that base, we will broaden our reach by
setting up a secured wide area network which will increase clinicians' access to
our extensive database of information and clinical experience for the management
of a full range of diseases. We believe our products and services can greatly
reduce the cost and increase the quality of life for the patients. To bring our
products to the market, Nanobac will form a proprietary reference laboratory
that offers physicians a comprehensive patient analysis and a Nanobiotic
therapeutic.
Nanobacterium Sanguineum Background and Description:
Nanobacterium sanguineum (nanobacteria) was discovered in 1988 by Finnish
researcher Olavi Kajander, M.D., Ph.D.. Dr. Kajander was carrying out mammalian
cell research when a routine mammalian cell culture experiment, using
commercially available fetal bovine serum as the growth media, just wasn't
getting off the ground. The cells weren't thriving and dividing like they
should; the cells were sickly and died off before any study could be done.
Strange vacuoles were forming up in many of the cells, and these cells
subsequently died. Dr. Kajander, like all basic cell researchers, had
encountered this problem before; sometimes their cell cultures worked, and
sometimes they didn't. Thankfully, Dr. Kajander researched this further and
after several weeks of culture, turbidity developed in one of the flasks. This
represented the first isolation of Nanobacterium sanguineum.
14
In 1991 Dr. Kajander was joined by microbiologist Neva Ciftcioglu, Ph.D. at the
University of Kuopio, Finland. Nanobacteria was the first nano-sized,
autonomous, self-replicating organism ever detected. Their research established
that the blood-borne nanobacteria forms slow-growing calcified colonies in
arteries and organs, much as coral reefs are formed. Nanobacteria have been
found in human and animal blood, urine and saliva. The name "nanobacteria" was
introduced and patented by Dr. Olavi Kajander as the name for very small
mineral-associated bacteria-like life forms. Nanobacteria produce apatite
minerals by building apatite envelopes or "castles" around themselves. They seem
to play a role in the formation of kidney stones and other calcification
diseases. Nanobacteria may be involved in biofilm formation, a common problem in
urinary stents and catheters. They may also cause chronic infections in humans
and animals.
Nanobacterium sanguineum is a small, slowly growing bacterium that can be found
in human blood, kidney stones, and arterial wall plaques. Nanobacteria are
10,000 to 100,000 times smaller than typical bacteria and, until recently, were
not detectable using conventional sterility testing methods. These bacteria tend
to cluster and form a protective calcium shell that shelters them from the
immune system and most antibiotics. Nanobacteria are cytotoxic (can cause damage
to cells), resistant to heat, hydrocholic acid, high-dose radiation, and most
antibiotics (See Table 1).
Nanobacteria are carbonate apatite forming bacteria and have the unique
capability to fix calcium and prothrombin upon their cell membrance, ultimately
forming a porous protective calcium encasement. Within this encasement, they
become semi-dormant (multiple slowly) and can build upon themselves somewhat
like a coral reef might enlarge upon itself. Their rate of replication is
approximately 44% annually. Nanobacteria are pleomorphic which means that they
have different physical forms and shapes during their life cycle. They can also
change appearance, form and alter function in response to various changing
environmental factors.
Nanobacteria in mammalian cells leads to abnormal cell growth, growth rates or
cell death and may lead to genetic alteration (mutations). Nanobacteria cannot
be grown in standard culture media but grow well in media supplemented with
mammalian blood or serum. Nanobacteria have been found in various mammalian
serum-derived or serum-supplemented products, such as fetal bovine serum and
vaccines. As these organisms pass through most sterilization filters in use
today, novel sterilization techniques are needed. These may include improved
filtration, radiation and chemical treatments. Due to their extremely small
size, nanobacteria can only be studied using scanning and transmission electron
microscopes or other recently developed high-resolution microscopes.
15
Table 1: Unique Properties of Nanobacteria
--------------------------------------------------------------------------------
Property Description
--------------------------------------------------------------------------------
Size: 0.05-0.5 nm
--------------------------------------------------------------------------------
Doubling Time: 3-6 days
--------------------------------------------------------------------------------
Morphology: Coccoid to coccobacillar
Cell wall 20-200nm
--------------------------------------------------------------------------------
Isolated From: Vaccines
Fetal Bovine Serum
Calcified carotid arteries
Aortic aneurysms
Cardiac valves
--------------------------------------------------------------------------------
Antibiotic Penicillin
sensitivity Macrolides
Quinolones
--------------------------------------------------------------------------------
Resistant to: Heat: 100(0)C for 1 hr
pH Change
UV radiation
Gamma-Irraditaion: 1 megarad
Formaldehyde, glutaraldehyde
--------------------------------------------------------------------------------
Sensitivity: 5-FU
Tetracycline HCl
Cytosine-arabinoside
Gamma-Irraditaion: >2.5 megarad
0.02 micron/20nm filter
1% Virkon(R) (disinfectant)
--------------------------------------------------------------------------------
Nanocteria may be a primitive life form. One recent study examining upper
urinary tract stones found particles resembling nanobacteria by scanning
electronic microscopy. A second study confirmed the existence of nanobacterial
particles isolated from human saliva and dental plaque that were culturable.
Some groups have confirmed the existence of nanobacteria by identification of
the organisms in polycystic kidney disease, in a North Carolina beef herd, in
human pineal tissue, in human atherosclerotic plaques, in calcified carotid
arteries, aortic aneurysms, caridac valves, cardiac stents, and ovarian cancer.
Nanobacteria are present in many isolates of pathological calcification (calcium
build ups in areas of the body where calcium should not be present). Therefore,
nanobacteria may be implicated in multiple diseases including but not limited
to: cardiac disease, kidney stones, polycystic kidney disease, arthritis,
ovarian cancer, and prostatitis.
16
Nanotechnology is the creation of useful, functional materials, devices, and
systems through controlling and manipulating matter on the nanometer-length
scale (1-100 nanometers), and exploiting novel phenomena and properties
(physical, chemical, biological, mechanical, electrical) at that length scale.
The prefix "nano" means a billionth - a nanosecond is one-billionth of a second,
a nanometer is one billionth of a meter, and so on. For comparison, the head of
a pin measures one million nanometers across. A red blood cell has a diameter in
the range of thousands of nanometers. Ten nanometers is 1,000 times smaller than
the diameter of a human hair. DNA molecules are about 2.5 nanometers wide. An
individual atom measures a few tenths of a nanometer in diameter.
There are medical professionals who assert that nanobacteria do not exist. They
contend that nanobacteria are artifacts, contaminants or crystalline growths. We
disagree with this contention. Our business model is based on the existence of
nanobacteria.
Research and Development
Our lead scientists Olavi Kajander, and Neva Ciftcioglu NASA/USRA, have formed
multidisciplinary alliances with renown researchers including: Hojatollah Vali,
McGill University, Canada; Mayo Clinic, Rochester; Garcia-Cuerpo, Spain; China
Changsha group; Sommer, Univ. of Ulm; Pretorius, South-Africa; G. Epstein/J.T.
Salonen; Tom & Marcia Hjelle, Univ. of Illinois; S. Epstein, Washington Hospital
Center, Washington DC; R. Berger, Miami Heart Institute, Miami FL; Y. Av-Gay,
University of British Columbia; and H. Gomez, Genbiomics.
To date, this collaboration has published over 80 articles, numerous abstracts
and book chapters. Example publications since 1998 include articles in Science,
Nature and Nature Medicine, Proceedings of the National Academy of Sciences,
Lancet, New Scientist, Molecular Medicine, PDA Journal, Kidney International,
Circulation, and American Society for Microbiology.
Biomedical Strategy
Potential biomedical applications include screening for and biosterilization of
nanobacterial contamination in products that will be used treating patients.
Injectable medical applications such as vaccines, blood products,
immunoglobulin, and IV fluids must be free of contaminants. Screening of
diagnostic support media such as culture media, and growth preparations is
critical in order to get the correct diagnosis. Biosterilization of Medical exam
equipment at the point of patient care and of implantable durable medical
devices such as hip replacements, cardiac valves, and stents will perhaps
mitigate or prolong the effectiveness of the device.
Bioindustrial Strategy
Potential bioindustrial applications include screening and biosterilization of
production line environments used for the preparation of cultures, vaccines, and
implantable durable medical equipment.
17
Government Regulation
Diagnostic laboratory operations are not regulated by the FDA. Our diagnostic
business is subject to regulation under the federal Clinical Laboratory
Improvement Act (CLIA). We will seek FDA guidance for our unique nanobiotic
therapeutic. We will comply with all FDA regulatory requirements.
Our contemplated activities and the products and processes that will result from
such activities will be subject to substantial government regulation.
Before new pharmaceutical products may be sold in the U.S. and other countries,
clinical trials of the products must be conducted and the results submitted to
appropriate regulatory agencies for approval. These clinical trial programs
generally involve a three-phase process.
Phase 1 includes the initial introduction of an investigational new drug into
humans. These studies are closely monitored and may be conducted in patients,
but are usually conducted in healthy volunteer subjects. These studies are
designed to determine the metabolic and pharmacologic actions of the drug in
humans, the side effects associated with increasing doses, and, if possible, to
gain early evidence on effectiveness. During Phase 1, sufficient information
about the drug's pharmacokinetics and pharmacological effects should be obtained
to permit the design of well-controlled, scientifically valid, Phase 2 studies.
Phase 1 studies also evaluate drug metabolism, structure-activity relationships,
and the mechanism of action in humans. These studies also determine which
investigational drugs are used as research tools to explore biological phenomena
or disease processes. The total number of subjects included in Phase 1 studies
varies with the drug, but is generally in the range of twenty to eighty.
In Phase 1 studies, CDER can impose a clinical hold (i.e., prohibit the study
from proceeding or stop a trial that has started) for reasons of safety, or
because of a sponsor's failure to accurately disclose the risk of study to
investigators. Although CDER routinely provides advice in such cases,
investigators may choose to ignore any advice regarding the design of Phase 1
studies in areas other than patient safety.
Phase 2 includes the early controlled clinical studies conducted to obtain some
preliminary data on the effectiveness of the drug for a particular indication or
indications in patients with the disease or condition. This phase of testing
also helps determine the common short-term side effects and risks associated
with the drug. Phase 2 studies are typically well-controlled, closely monitored,
and conducted in a relatively small number of patients, usually involving
several hundred people.
18
Phase 3 studies are expanded controlled and uncontrolled trials. They are
performed after preliminary evidence suggesting effectiveness of the drug has
been obtained in Phase 2, and are intended to gather the additional information
about effectiveness and safety that is needed to evaluate the overall
benefit-risk relationship of the drug. Phase 3 studies also provide an adequate
basis for extrapolating the results to the general population and transmitting
that information in the physician labeling. Phase 3 studies usually include
several hundred to several thousand people.
In both Phase 2 and 3, CDER can impose a clinical hold if a study is unsafe (as
in Phase 1), or if the protocol is clearly deficient in design in meeting its
stated objectives. Great care is taken to ensure that this determination is not
made in isolation, but reflects current scientific knowledge, agency experience
with the design of clinical trials, and experience with the class of drugs under
investigation.
The results of the preclinical and clinical testing of a biologic product are
then submitted to the FDA in the form of an Application to Market a New Drug,
Biologic or an Antibiotic Drug for Human Use (Title 21, Code of Federal
Regulations, 314 & 601) or Biologics Licensing Application (BLA). In response to
a BLA, the FDA may grant marketing approval, request additional information or
deny the application if it determines the application does not provide adequate
basis for approval. The receipt of regulatory approval often takes a number of
years, involving the expenditure of substantial resources and depends on a
number of factors, including the severity of the disease in question, the
availability of alternative treatments and the risks and benefits demonstrated
in clinical trials. On occasion, regulatory authorities may require larger or
additional studies, leading to unanticipated delay or expense. Even after
initial FDA approval has been obtained, further clinical trials may be required
to provide additional data on safety and effectiveness and are required to gain
clearance for the use of a product as a treatment for indications other than
those initially approved. In addition, side effects or adverse events that are
reported during clinical trials can delay, impede, or prevent marketing
approval. Similarly, adverse events that are reported after marketing approval
can result in additional limitations being placed on the product's use and,
potentially, withdrawal of the product from the market. Any adverse event,
either before or after marketing approval, could result in product liability
claims against us.
In connection with the commercialization of products, it is necessary, in a
number of countries, to comply with certain regulations relating to the
manufacturing and marketing of such products and to the products themselves. For
example, the commercial manufacturing, marketing and exporting of pharmaceutical
products require the approval of the FDA in the U.S. and of comparable agencies
in other countries. The FDA has established mandatory procedures and safety
standards which apply to the manufacture, clinical testing and marketing of
pharmaceutical products in the U.S. An example of this is the FDA's current Good
Manufacturing Practices (or GMP). Before approval of a product, the FDA will
perform a pre-licensing inspection of the manufacturing facilities to determine
their compliance with GMP and other rules and regulations. In complying with
GMP, manufacturers must continue to expend time, money and effort in the area of
production and quality control to ensure full compliance. After the
establishment is licensed for the manufacture of any product, manufacturers are
subject to periodic inspections by the FDA. Any determination by the FDA of
manufacturing related deficiencies could have a material adverse effect on our
business.
19
The regulatory requirements and approval processes for new products in the EU
and Canada operate under similar principles as those applied in the U.S. The
process of seeking and obtaining approval of the FDA or regulatory authorities
in the EU or other regulatory authorities worldwide for a new product and
licensing of the facilities in which the product is produced takes a number of
years and involves the expenditure of substantial resources. In addition, the
regulatory approval processes for products in the U.S., the countries of the EU
and other countries around the world are undergoing or may undergo changes. We
cannot determine what effect any changes in regulatory approval processes may
have on our business.
Environmental Matters
We have not been impacted financially or operationally by environmental laws.
HealthCentrics Business Unit
Prior to acquiring NanobacLabs Pharmaceuticals, Inc., our sole operating
business unit was HealthCentrics. This Business unit develops and markets
web-based medical accounting, billing and management information services to
third party billing companies, practice management and healthcare provider
organizations.
During October 2003 we decided to sell our HealthCentrics subsidiary, because of
our decision to focus on nanobacteria,. In addition, earlier plans to develop
multiple initiatives in healthcare, building products, and waste solutions will
not be pursued. We believe that a total focus on nanobacteria will maximize
shareholder value. During March 2004, HealthCentrics was sold to an affiliate of
the Chairman and CEO for $250,000.
Geographic
We will initially focus our business in the United States and Canada. To date,
over 95% of our revenue is from the United States. We also plan to develop our
markets in the European Union through the operations of our Finnish Subsidiary,
Nanobac OY.
Employees
We have seven employees in our corporate headquarters in Tampa, Florida and five
employees in Finland. There are currently no employees in the HealthCentrics
business unit.
Factors That May Affect NNBP
We operate in a rapidly changing environment that involves a number of risks,
uncertainties, and assumptions, many of which are beyond our control. For a
discussion of some of these risks, see "--Risk Factors" in the MD&A section of
this report included under Item 7. Other risks are discussed elsewhere in this
Form 10-K.
20
Investor Information
We are subject to the information requirements of the Securities Exchange Act of
1934 (the "Exchange Act"). Therefore, we file periodic reports, proxy
statements, and other information with the Securities and Exchange Commission
(the "SEC"). Such reports, proxy statements, and other information may be
obtained by visiting the Public Reference Room of the SEC at 450 Fifth Street,
NW, Washington, DC 20549 or by calling the SEC at 1-800-SEC-0330. In addition,
the SEC maintains an Internet site (http://www.sec.gov) that contains reports,
proxy and information statements, and other information regarding issuers that
file electronically.
Financial and other information about NNBP is available on our website
(http://www.nanobaclabs.com). We make available on our website, through links to
the SEC website, copies of our annual report on Form 10-K, quarterly reports on
Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or
furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as
reasonably practicable after filing such material electronically or otherwise
furnishing it to the SEC.
21
© 1995-2006 EDGAR Online, Inc. All rights reserved.
Terms of Use | Privacy Statement
Rob
From RB "AVTX" board..
By: sonk1
07 Feb 2007, 12:40 AM EST
Msg. 11855 of 11859
(This msg. is a reply to 11853 by bluebird77-7.)
Jump to msg. #
i see. you didn't answer the question. no matter. it's not important.
mark feb 22nd on your calender. it just may surprise you. oh, and mark may 8th, and just for fun, mark nov 7th. they all should mark important turning points in this stock. good nite.
Could be wise to keep an eye on these dates..for "AVTX"
IMO thank you Jolyn
"Stockcharts.com shows a Bollinger Band inversion"
Don't trust the charting M&M's are playing games with then..
or 2 good daytraders of the Jim Bishop class ...
odds are M&M's
IMO Thank you Jolyn
"----Sonk,,,Eat your heart out!" lol
"Annie can't get filled and it went from .02 to .023 on 5000 shares"
Got some as well...
We will see what happens monday..
IMO thank you Jolyn
batscam_reloaded and new investors
The con stops here
These links will post in IHUB and you know we can't show
the Volume...
As a rule the value of a stock drops from 20% to 40%
Once Illegal hedge funds start shorting a stock..
With "MRKL" we could be looking a
3000%+ drop in value..
Also some companies have went out of business over Illegal
shorting
This will not be the case with "MRKL" becaues of the "TCNH"
spin-off or dividend..
The shorting problem is so big with "MRKL" even the SEC will
have problems.
[more on that in another post..]
This is why that "MRKL" could be the best investment ever..
Time will prove me right..
Even our M&Ms are going to have a big problem..
MY CALL HOLD OR BUY "MRKL"
http://finance.yahoo.com/q/bc?t=2y&s=LN8.BE&l=on&z=m&q=l&c=mrkl.pk
WKN 727587
MARKLAND TECH (WKN 727587)
How about Deutschland
http://de.finance.yahoo.com/q?s=LN8.BE
http://de.finance.yahoo.com/q?s=MRKL.PK
MARKLAND TECH (WKN 727587)
IMO thank you
ironyman and all have been picking up a few shares..
of "AVTX" and "NNBP"
from my new brokerage account with Bank of America..
[free trades lol]
Don't worry I am not giving up my e-trade account or
shares.. I am now useing both accounts..
Charts are starting to look good goood again for
"AVTX" We need news
Merry Christmas to you and all
IMO Jolyn
Rob Phillips
Thank you for the offer..but I can't
All of us pay our own way..
Merry Christmas to you and your family..
Thank you Jolyn
gold-nugget,Cytotekk,ironyman,loss_slayer
Next week I will be in Guatemala to build a new Church..
Then to El Salvador and do the same again..
I will be outside the United States for a while..
All of you needed to be toughened up..
With a little Anti-Digrdoug training..
Sorry no one got an A
Cytotekk got the only B
Now Rob's move [#3398]was sharp and good
by pulling the focus away from me.
Too bad no one picked up on it..
Sir Bradan got the F
When "AVTX" is between 0.05 and 0.15 we will see
real Bashing..above 0.15 a new class of bashers..
On IHub we attack the Message only, not the
Messager..Change the focus..Same for SI
RB Lie about the Messager and attack the Message.
Change the focus if needed..
Text Features: bold, Italic, Underline
Use it
IMO Thank you Jolyn
Bad humour or truth?? gold-nugget
Would you care to prove me wrong...
Gary could be as dead as this stock..
How old is he 72 ?
He could be in a rest home..?
His mind gone..?
IMO Thank you Jolyn
ironyman "It's not going to go sub-penny. Get over it."
Is too,Is too
"Whenever Gary gets around to doing an"
For all we know good old Gary could be in a pine
box under 6 feet of Texas Bull Dodo..
Try putting up 10,000 shares of "AVTX"
at 0.10 and see what happens...
IMO Thank you Jolyn
loss_slayer AVTX.OB -8.57% Death March
"would't it be great if you are wrong?"
I wish that I could be wrong..
Once I thought I was wrong.
But I wasn't...
All of you should sell and re-buy AVTX.OB @0.005
Do just like I did with "MYNG" sold at 0.105
came back in at a lower price..
And made a good profit...
IMO Thank you Jolyn
loss_slayer "Still hold and subpenny?"
Yup but my "AVTX" grew in value today..
If I am wrong so be it..
IMO Thank you Jolyn
gold-nugget "great crystal ball she haves!!!"
"The lady who once stated 200 for a gold stock --"
Yes looking into my great crystal Ball..
"Note that Annie posts a lot of DD on RB, and she quotes Rod Steel a lot."
http://www.siliconinvestor.com/readmsg.aspx?msgid=18361781
From: gold-nugget
http://www.siliconinvestor.com/readmsg.aspx?msgid=18510577
From: gold-nugget of 33953
"Golden Eagle Celebrates Surpassing Milestone of 3,000 Troy Ounces and $1 Million in Revenue by Offering the Cangalli Mine's First One-Ounce Gold Nugget,."
http://www.siliconinvestor.com/readmsg.aspx?msgid=19045280
From: Ironyman of 33953
LMAO about Cyclops being removed as moderator and made my day. Thanks Colleen.--Eric
Jim Bishop River of Gold.. About 1 mile wide
25 miles long
Douglas Lapp mine after mine..on the cangalli claim
what this..
http://www.siliconinvestor.com/readmsg.aspx?msgid=18555248
Fred C. Dobbs,
Only BFDeal may have the DD that I have..
"IMO "MYNG" is hit the sub-pennies last friday just like
I said it would.When "MYNG" was 0.105
As for my call of $200 a share for "MYNG"
Others on SI and RB Stated the "MYNG" could go
even highter..
Problem "MYNG" stated they could mine the gold for
$75 an oz the truth "MYNG" could not mine it for
$500 an oz.. Then they lied about it IMO"
http://www.investorshub.com/boards/read_msg.asp?message_id=14374130
IMO Thank you Jolyn the Good
ironyman Let gold-nugget have his nap.. He can wake up
to "AVTX" selling in the sub-pennies..
[and I will be buying]
But then I don't know anything about stock..
Have a look at "NNBP" and "MRKL"
My portfolio is in the GREEN... Yours?
IMO Thank you Jolyn
It seems that the shorting of "MRKL" has stopped..
http://finance.yahoo.com/q/bc?s=LN8.BE&t=3m&l=on&z=m&q=l&c=mrkl.ob
Well here is a little more..
http://finance.yahoo.com/q/bc?t=5d&s=MRKL.PK&l=on&z=m&q=l&c=ln8.be
Look at the letters in these links..
"MRKL" spin-off is due any time..
Its bad luck if you a holding a short position
in a stock and they have a spin-off..
IMO Thank you Jolyn
insider01 What a post everyone should e-mail you post
to everyone they know its well worth reading..
"@.50? Watch PR of NNBP, marcet of 500 000 000 are possible?"
Look: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Someone should post this to RB..
I don't have a account with them..
IMO Thank you Jolyn
loss_slayer
"Yep, your credibility is is going sub not this stock."
"jolyn you are really hurting your credibility with that kind of wild specutlation.You rec a hold while buy at sub penny..."
Time tells all
"My OPINION IS THIS ABOUT BERLIN....THEY WILL SHORT ALRIGHT BUT ONLY AND ONLY AFTER THIS FLIES..they the shorts might just have the position......does not mean they are shorting at this time."
Your just wrong here.. as well look at the BE charting..
"this stock is going to fall some 250 percent?"
Yes!! If they don't come with some good news..
This is a shake-out.. Life is not fair..
"Sub penny? Not going to happen unless someone wants to sell very cheap into low volume just to say I told you so"
What your not understanding..IS that in this point in
time with "AVTX".. Unless you are selling or know someone that is selling..
NO ONE knows if that trade was real
Shorting gets ugly fast..
"you that was calling for myng to be 4oo dollars a share or was it a thousand.....where is it now?"
IMO "MYNG" is hit the sub-pennies last friday just like
I said it would.When "MYNG" was 0.105
As for my call of $200 a share for "MYNG"
Others on SI and RB Stated the "MYNG" could go
even highter..
Problem "MYNG" stated they could mine the gold for
$75 an oz the truth "MYNG" could not mine it for
$500 an oz.. Then they lied about it IMO
"Don't tell me jolyn put out a naked picture of herself and it caused a fight.I wouldn't be funny..unless she ended up being a transvestite. lol Is she....is that what it was all about. lol"
Eat your little heart out..
Too bad Cytotekk and I are not fighting..
IMO Thank you Jolyn
ironyman You have some good points.. The only
reason I am comparing is for shorting and spin-off..
As for the value...
"MRKL" owns 66% of "TCNH" After the spin-off..
"TCNH" should go to $8.00 a shares..
The problem with "MRKL" is I don't trust them..
They don't have a good history..
Time tells all..
As for the charting on "AVTX" the shorting is
takeing its toll..
We can't put a lot of trust in the charts..
IMO Thank you Jolyn
ironyman For once I may have a good answer..
As in my last post I stated that "MRKL"
http://www.investorshub.com/boards/read_msg.asp?message_id=14355930
was being shorted far more the "AVTX"
and that "MRKL" has a spin-off the same as "AVTX"
Only "MRKL"'s spin-off is due any time..
It seems that the shorting of "MRKL" has stopped..
http://finance.yahoo.com/q/bc?s=LN8.BE&t=3m&l=on&z=m&q=l&c=mrkl.ob
Well here is a little more..
http://finance.yahoo.com/q/bc?t=5d&s=MRKL.PK&l=on&z=m&q=l&c=ln8.be
Look at the letters in these links..
If I am right about this the same thing will
happen to "AVTX" if "AVTX" ever has a spin-off..
New call for "AVTX"
Hold and only Buy "AVTX" in the sub-pennies
http://finance.yahoo.com/q/bc?t=1y&s=XT6.BE&l=on&z=m&q=l&c=avtx.ob
Let them Short us.. Play to win
LOL I bought a pile of "MRKL" last week @ 0.007
and a pile of "NNBP" Hummm take some the profit and buy more
"AVTX" in the sub-pennies...
I am working on other DD for "AVTX"
May the best lady make the most profit..
IMO Thank you Jolyn
loss_slayer "more about the naked photo fight."
Sorry not this week and Only if we get into it..
Plus not sure who won that one.. Poor slaphappy
went bannas as well..
Plus we don't dare fight on IHub.. As we have
one rule.. [No Rules]
Now my poor little portfolio is up again
no thanks to "AVTX" but thanks to "NNBP"
I think I will try to flip it at 0.48
I feel that it can go to 0.50 this round..
IMO Thank you Jolyn
Cytotekk "maybe she will and I can get her shares."
How sweet my shares will bring you good luck to..
We both have E-Trade accounts too..
We should be able to sell our shares to each other..
Because we are friends and you need to make
a good profit I will drop my price 50%
How about 100,000 shares @ $1.39 per share..
We know this is going to $7.00 a share.
That will teach ironyman and gold-nugget
that you can out smart them two in getting the
Real "Lucky Annie "AVTX" shares"..
Speed counts before there all gone..
Get your "Lucky Annie "AVTX" shares" now..
IMO Thank you Jolyn
ironyman "...I'll bet Annie dumps."
That could be a bad bet..
But I will post something after I sell..
Like I did with "MYNG"
"XT6.BE got hammered..."
I may have a part answer
"MRKL" has been shorted far more than "AVTX"
"MRKL" shareholders will receive 1 share of Technest common stock for every 194 shares of Markland common stock they owned.
This [IMO] stock is ran by a bunch of morons or crooks
"MRKL" has been shorted from 0.13 to 0.007
A new spin-off date will be out is a few weeks or less..
The bashing is pro in RB same ones for the last 2
years..
I just bought more "MRKL" at 0.007
My bet is better than your bet..
We need to see what happen with this stock..
IMO Thank you Jolyn
Those who sold today should come back
in a year an say hi to us..
Please Enjoy Your Profit..Its Yours you earned it..
If anyone don't understand why this stock "NNBP"
can shoot to $15+ a share..
You have not done your DD on "NNBP" ..
My call Hold or BUY
Good luck to All
IMO Thank you Jolyn
Cytotekk well I can't see fighting with you yet
I have made my point save my posts and we will
see who is right...For now I will not Bash
In the meantime I am working on some
NEW DD for "AVTX";
If it is bad I will not post it..
I will e-mail to you and a few others on this board only..
We owe this to each other..
You know my english it will a
few days before this done..
Its past your bed time go to bed..
IMO Thank you Jolyn
Cytotekk "Annie, is this change in your posting
outlook a Halloween joke??"
No This Is Ball Halloween joke on "AVTX" investors..
Here is your math problem for the day..
An fathful "AVTX" investor has 200,000 free shares of "AVTX"
and 37,500 flipping shares @0.059 ....
"AVTX" drops -3.85%
What is the value of the loss to the
200,000 free shares?
What is the value of the loss to the
37,500 flipping shares?
Get gold-nugget and ironyman to help you..
Well too hard how about how maney "AVTX" shares..
can you buy with a $1000 @0.005??
"possessed by an irrational Alaskan demon basher spirit"
Sorry I belived in God and Jesus
"You will not see this go subpenny as long as I am long, trust me."
LOL Like when all of us were pumping "MYNG" at 0.30
and You and gold-nugget and ironyman were dumping
your "MYNG" shares..
and I was buying more "MYNG" shares??
Oops what this..
By Cytotekk
"I am not a flipper"
http://www.investorshub.com/boards/read_msg.asp?message_id=14320701
Now I am not going say it..But you should go to
confession..
If we have to fight we can go to the RB old "MYNG"
posts and cut and paste the old posts..
The nude photo fight was a good one..
"PS, are you hard up for cash and need a run???"
Nope I extra money to invest.. Every one repaid their
loan. I gave on their PFD..
IMO Thank you Jolyn
=====================================================
Posted by: gold-nugget
"IF YOU BASH OVER AT NITEGLE BOARD YOUR POSTS WILL BE REMOVED!
LOOK AT WHO IS THE MODERATORS AND ASSISTANTS ---"
http://www.investorshub.com/boards/read_msg.asp?message_id=14283035
Posted by: Cytotekk
"If you plan to do that, follow the TOU. I know how to use the delete feature as a moderator."
http://www.investorshub.com/boards/read_msg.asp?message_id=14278527
Posted by: loss_slayer
"So what is holding it back?I do not blame jolyn for being distressed over the lack of movement here with AVTX. That is what ticks me off about Ball.........."
http://www.investorshub.com/boards/read_msg.asp?message_id=14286776
Posted by: jolyn86
"We are looking at a new up coming low for "AVTX"..
We need to wake up good old Mr. Gary E. Ball..."
http://www.investorshub.com/boards/read_msg.asp?message_id=14277223
"gold-nugget "AVTX" -3.85% Down we go Weeeeeeeeeeeeeeeeeee
Next stop new new year to date low..
Next next stop SUB-PENNIES!!!"
http://www.investorshub.com/boards/read_msg.asp?message_id=14318668
IMO Thank you Jolyn
gold-nugget "AVTX" -3.85% Down we go Weeeeeeeeeeeeeeeeeee
Next stop new new year to date low..
Next next stop SUB-PENNIES!!!
Be happey don't cry you know its coming..
Everyone called me a moron and other names
when I dumped "MYNG" at 0.105 and stated
that "MYNG" would go sub-penny..Oops what happend?
I was the one who first posted the shorting
of "AVTX" in SI..
Now good old ironyman has had to much Billy Beer[post 3279]
He thinks the M&M's are shorting
"AVTX" thru the Berlin Exchange
Fact is it could be "AVTX" it self..
Its happend before or any one of us..
You trust every poster on these boards?
Now I have a few ways to go on "AVTX"
1. Sell "AVTX" Use the tax-write-off
A. Re-Buy "AVTX" in the Sub-Pennies
flip it and turn "AVTX" into a profit..
Just like I did with "MYNG"
B.Because of "MRKL" and "NNBP" I will need
a good tax-write-off. Now my stock Portfolio
took a big jump up today even with
"AVTX" -3.85% How did your Portfolio do?
Too bad you did jump into "NNBP" I told
everyone [its not to late]
2. Should I fight with you,ironyman,Cytotekk,
on the Niteagle Sytems, Inc. board..
A.Do you have a better plan?
We, not "AVTX" will have to kick start "AVTX"
This shake-out is not over..
This shorting is adding up..
They don't dare to stop.
Its so bad Tech Charting now is worthless..
B.If I chose to fight.
1 "AVTX" could get hurt
2 I can't fight the 3 you in on that Board..[yet]
3 Hit and Run on all "NNBP" boards
Now thats said, have a nice day..
By now you should know that I have a taste for stock
that can go from pennies to Dollars
Lets never forget "MYNG" $200 a share..
My little list
"NNBP" can go to $15+ a share
"AVTX" can go to $7 a share
"NGLE" can go to $5 a share after it hits the Sub-Pennies
-------------------------------------------
Too bad I had to removed "MYNG" and "MRKL"
However "MRKL" could see a $1.00 a share..[not the best bet]
gold-nugget will I have to remove "AVTX" ??
IMO Thank you Jolyn
=====================================================
Posted by: gold-nugget
"IF YOU BASH OVER AT NITEGLE BOARD YOUR POSTS WILL BE REMOVED!
LOOK AT WHO IS THE MODERATORS AND ASSISTANTS ---"
http://www.investorshub.com/boards/read_msg.asp?message_id=14283035
Posted by: Cytotekk
"If you plan to do that, follow the TOU. I know how to use the delete feature as a moderator."
http://www.investorshub.com/boards/read_msg.asp?message_id=14278527
Posted by: loss_slayer
"So what is holding it back?I do not blame jolyn for being distressed over the lack of movement here with AVTX. That is what ticks me off about Ball.........."
http://www.investorshub.com/boards/read_msg.asp?message_id=14286776
Posted by: jolyn86
"We are looking at a new up coming low for "AVTX"..
We need to wake up good old Mr. Gary E. Ball..."
http://www.investorshub.com/boards/read_msg.asp?message_id=14277223
IMO Thank you Jolyn
loss_slayer Thank you for being truthfull
I feel that "AVTX" is going sub-pennies..
if not a new low.. Charting shows it..
Ball and only Ball can stop it..
He is letting down his investors
There is no reason for this to happen..
Too bad some on these boards don't believe
in Freedom of Speech..
IMO Thank you Jolyn
"HOW DARE YOU SAY THOSE THINGS ABOUT BALL"
Would you like to prove me wrong?
I will say it again
"Because of "AVTX" is not reporting news
Ect ect... "AVTX" is becoming a con
Blame Mr. Gary E. Ball ONLY!!
The "AVTX" investor should be and will be rewarded
first.."
Now please prove me wrong.
and tell us all about the return on your investment
that Mr. Gary E. Ball given you for investing in "AVTX"..
"AVTX IS NOT A CON --"
Well prove me wrong back up what your saying..
How long have we been pumping money into this
stock?
Unless something happens fast we are looking at
a new low for "AVTX"..
"YOUR SPEAKING GIBERISH AGAIN -"
You know this is not true..
"IF YOU BASH OVER AT NITEGLE BOARD YOUR POSTS WILL BE REMOVED!
LOOK AT WHO IS THE MODERATORS AND ASSISTANTS ---"
Its bad luck to threaten me..
IHub is not the only boards..
IMO Thank you Jolyn
ironyman and All
We are looking at a new up coming low for "AVTX"..
We need to wake up good old Mr. Gary E. Ball...
He is to work for us or he can step down..
I am tired of his games or shake out..
I have too much money in "AVTX" to play games.
We have too keep buying and Holding "AVTX"..
"NGLE" Must be stopped..
To open their sorry eyes..
Because of "AVTX" is not reporting news
Ect ect... "AVTX" is becoming a con
Blame Mr. Gary E. Ball ONLY!!
The "AVTX" investor should be and will be rewarded
first..
We have no choice "NGLE" Must be stopped..
If "AVTX" is a con so is "NGLE"
All "AVTX" investors must protect their "AVTX" investment..
Meaning we must go into all the "NGLE" boards
and BASH!!!
IMO Thank you Jolyn
Just got more "MRKL" @00.007 This is my 4th buy-in..
This brings down my avg cost to 0.019
Well lets see about this 0.05 a share..
IMO Thank you Jolyn
loss_slayer Good to see you back posting
on this board..
E-mail me the next time you flip this stock..
Its getting old to set so long on this
stock.. However the next time you see
or talk to good old Mr. Gary E. Ball
You can tell him that the "NGLE" con will
not fly until "AVTX" has its spin-off
and "AVTX" is over a $1.00 a share..
I have been putting out the truth about
"NGLE" on other "NGLE" boards as well..
Cytotekk,ironyman,bradan are a little unhappy
with me..
The point is I am getting a lot of Money into
"AVTX" and I want a return on my investment now.
You should go over to that board and read some of my
posts..
I will be buying more of another stock in the
morning..
IMO Thank you Jolyn
goldenegg Just put in another order.. I hope I
am right.. ask is 0.02 my bid 0.0071
Tech charts on this say Down..
Time tells all..
IMO Thank you Jolyn
Cytotekk "Jolyn, what on earth on you doing???"
Well I made a cake today and we are having our
first snow.. So its time to spend some on my
little computer.. We do have long cold winters..
and I have protect new investors
from stock cons..
"Are you calling this start up company a con??"
Please prove me wrong..
Show us one of your DD pages of this worthless stock.
Only god knows how maney shares they have out there now.
What the float now billion shares? Prove me wrong.
When was the last stockholder meeting?
How maney exchanges is "NGLE" being
traded on? You don't know and can't prove it
can you..
"NGLE" needs cash and the first round of investors..
are going to lose their money..and you know it.
How maney "NGLE" shares are you getting to pump this stock?
Cytotekk in all your posts I can't find one stating
that own "NGLE"
Now I have a buy order at the true value for "NGLE"
"Bradan, I thought you were going to
basically ignore Jolyn's rants."
Now this hurts..Bradan is only trying to be a top member
of your team..
Give him some time he will learn how to fight the truth.
All of this is in my very humble opinion
Thank you Jolyn
------------------------------------------------
""AVTX"/"NGLE"/I-6 to understand one
you must understand all 3"
http://www.investorshub.com/boards/read_msg.asp?message_id=12661374
For DD that you can trust please go here..
http://www.investorshub.com/boards/read_msg.asp?message_id=12661374
"bradan NGLE.PK near shell want proof.."
http://www.investorshub.com/boards/read_msg.asp?message_id=14199404
Oh? Oh no lets have look.."
http://www.investorshub.com/boards/read_msg.asp?message_id=11747613
NGLE: Niteagle Sytems, Inc. Easy DD
http://www.investorshub.com/boards/read_msg.asp?message_id=11654878
""NGLE"Change: -0.54 -72.00% You better get into another
stock"
http://www.investorshub.com/boards/read_msg.asp?message_id=11713594
"Lets think this out out..ironyman"
http://www.investorshub.com/boards/read_msg.asp?message_id=12635636
"Dear bradan you have open my eyes about Niteagle Sytems, Inc."
http://www.investorshub.com/boards/read_msg.asp?message_id=12649236
IMO Hugs and Kisses
Thank you Jolyn
All of this is in my very humble opinion
New Investors too bad Market depth is not
available for "NGLE" Well see fou yourself..
http://www.investorshub.com/boards/quotes.asp?ticker=NGLE&qm_page=417&qm_symbol=NGLE
This means at least 1 of 4 things
1. All or part of the shares traded are Short..
a.None of us will be able to tell.. Sorry
2. Mass share dumpng by Niteagle Sytems, Inc.
a.None of us will be able to tell.. Sorry
3. As for share trades we don't know if they are real..
a.None of us will be able to tell.. Sorry
4. 1 thru 3 could be true at the same time..
a.None of us will be able to tell.. Sorry
Why is it most charting sites
don't have anything on "NGLE"??
Ever hear the word CON?
Sorry but then its your money..
All of this is in my very humble opinion
Thank you Jolyn
------------------------------------------------
""AVTX"/"NGLE"/I-6 to understand one
you must understand all 3"
http://www.investorshub.com/boards/read_msg.asp?message_id=12661374
For DD that you can trust please go here..
http://www.investorshub.com/boards/read_msg.asp?message_id=12661374
"bradan NGLE.PK near shell want proof.."
http://www.investorshub.com/boards/read_msg.asp?message_id=14199404
IMO Hugs and Kisses
Thank you Jolyn
All of this is in my very humble opinion